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Abstract 
Incidence of chronic heart failure (HF) increases with age and cardiovascular morbidity. 
Comorbidities increase hospitalization and mortality in HF, and non-cardiovascular 
comorbidities may lead to preventable hospitalizations. We studied the impact of 
comorbidities on mortality and morbidity in SHIFT, and investigated whether the impact of 
ivabradine was affected by comorbidities. We analyzed the SHIFT population, with moderate 
to severe HF and left ventricular dysfunction (in sinus rhythm with resting heart rate e70 
bpm), according to comorbidity: chronic obstructive pulmonary disease, diabetes mellitus, 
anemia, stroke, impaired renal function, myocardial infarction, hypertension and peripheral 
artery disease. Comorbidity load was classed as: 0, 1, 2, 3, 4+ or 1–2 comorbidities or 3+ 
comorbidities. Comorbidities were evenly distributed between the placebo and ivabradine 
groups. Patients with more comorbidities were likely to be older, female, had more advanced 
HF; were less likely to be on beta-blockers, with an even distribution on ivabradine 2.5, 5 or 
7.5 mg bid and placebo at all comorbidity loads. Number of comorbidities was related to 
outcomes. Cardiovascular death or HF hospitalization events significantly increased 
(p<0.0001) with comorbidity load, with the most events in patients with >3 comorbidities for 
both, ivabradine and placebo. There was no interaction between comorbidity load and the 
treatment effects of ivabradine. Hospitalization rate was lower at all comorbidity loads for 
ivabradine. In conclusion, cardiac and non-cardiac comorbidities significantly affect 
cardiovascular outcomes, particularly if there are >3 comorbidities. The effect of heart rate 
reduction with ivabradine is maintained at all comorbidity loads. 
Key words: heart failure, heart rate, ivabradine comorbidity, comorbidity, cardiovascular 
death   
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The prevalence and incidence of chronic heart failure steadily rises with increasing 
age and cardiovascular morbidity. The care of heart failure patients becomes more 
complex due to aging-related cardiac and non-cardiac comorbidities (1), disabilities 
(2) and frailty (3). Moreover, treatment is progressively complicated by changes in 
drug pharmacokinetic and pharmacodynamics in the elderly (4), and with increased 
polypharmacological therapy (5).  This is associated with increased economic burden 
for health care providers (6). Comorbidities increase hospitalization and mortality 
(7,8). It is unknown whether an increase in non-cardiovascular comorbidities affects 
the efficacy of proven medications. The SHIFT (Systolic Heart Failure Treatment with 
the If Inhibitor Ivabradine Trial) study tested the effect of heart rate reduction with the 
If- inhibitor ivabradine in patients with systolic heart failure, left ventricular ejection 
fraction (LVEF) d35%, in sinus rhythm and with resting heart rate e70 bpm on 
maximized guidelines-directed background therapy (9). SHIFT showed a significant 
reduction of cardiovascular death and heart failure hospitalization with ivabradine-
induced heart rate slowing (10). In the current post-hoc analysis, we studied the 
impact of preexisting comorbidities on mortality and morbidity in the SHIFT 
population and the treatment effect of ivabradine in the presence of comorbidities.  
 
Methods  
The design and the main results of SHIFT have been published previously (9-
11). In brief, SHIFT was a randomized, placebo-controlled, double-blind clinical trial 
in patients with moderate to severe heart failure and LV dysfunction (LVEF d35%).  
Patients in sinus rhythm, >18 years of age with a resting heart rate e70 bpm at two 
consecutive visits, were randomized to either ivabradine or placebo. Ivabradine was 
started at 5 mg bid and adjusted when necessary to either 7.5 mg or 2.5 mg bid 
depending on heart rate and tolerability.  All SHIFT investigators were expected to 
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include patients taking evidence-based medications at maximally tolerated doses for 
heart failure (including beta blockers). When a patient was not on a beta-blocker, or 
not on evidence-based target doses of beta-blocker, investigators were required to 
explain why and record the reasons in a dedicated case report form (CRF). The 
primary endpoint was a composite of cardiovascular death or hospital admissions for 
worsening of heart failure. All the study endpoints were adjudicated by an 
independent endpoint validation committee (9,10). The 8 most prominent 
comorbidities; chronic obstructive pulmonary disease (COPD), diabetes mellitus, 
anemia, stroke, impaired renal function (glomerular filtration rate <60 mL/min), 
myocardial infarction (MI), hypertension and peripheral artery disease (PAD) were 
reported in CRFs and evaluated. We studied the association of 1, 2, 3 and 4+ 
comorbidities on cardiovascular and non-cardiovascular outcomes and to increase 
sample sizes in 0 comorbidities, 1–2 comorbidities and 3 or more comorbidities.  
Descriptive statistics are presented as means and standard deviation (SD) for 
continuous variables and as numbers and percentages for categorical variables. For 
baseline characteristics, the pooled placebo and ivabradine groups were divided into 
groups with different comorbidity loads (1, 2, 3, 4+ or 0, 1-2, 3+ comorbidities). 
Baseline characteristics were compared between the comorbidity groupings using 
ANOVA for continuous variables and a chi-square test for categorical variables. All 
time to event regression analyses were based on Cox proportional hazard models.  
Hazard ratios (HRs) and 95% confidence intervals were estimated, and p-values 
were calculated from the Wald statistic. Time to event curves for each treatment arm 
comorbidity group was estimated using the Kaplan Meier method. The effect of 
comorbidity load on cardiovascular outcomes was assessed, in each treatment group 
separately, unadjusted and adjusted for beta blocker use, New York Heart 
Association (NYHA) class, ventricular ejection fraction (LVEF), heart rate, ischemic or 
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non-ischemic pathology, age and systolic blood pressure (SBP). The treatment effect 
of ivabradine versus placebo was assessed in the comorbidity groups separately. We 
tested for evidence of a difference in the estimated treatment effect between the 
comorbidity groups by adding a multiplicative interaction between treatment and 
comorbidity group. Logistic regression analysis was used to assess each 
comorbidity’s value as a predictor of heart rate (above/below 75 bpm). The outcomes 
analyzed were the primary endpoint (composite of cardiovascular death or hospital 
admission for worsening of heart failure) as individual components as well as death 
from heart failure or all-cause death, cardiovascular hospitalizations, total 
hospitalizations and non-cardiovascular hospitalizations. SAS (version 9.2) was used 
for all statistical analyses.  
 
Results  
Baseline characteristics of all patients and the impact of comorbidities on 
baseline characteristics are depicted in Table 1. Patients with higher numbers of 
comorbidities and in particular with 3+ comorbidities were likely to be older and more 
likely to be female with HF of ischemic origin. Furthermore, these patients also 
tended to have higher LVEF and more advanced clinical classes of heart failure. 
Patients with more comorbidities were less likely to be on beta-blockers, but there 
were similar distributions of ivabradine and placebo between the different comorbidity 
groups.  
There was an even distribution of comorbidities between placebo and 
ivabradine (Figure 1). The most common comorbidity was history of hypertension, 
followed by myocardial infarction, diabetes and impaired renal function, COPD, 
anemia, stroke and peripheral artery disease. The majority of patients had 1, 2 or 3 
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comorbidities (Figure 2A), with 35.7% on ivabradine and 37.4% on placebo in 
patients with 3 or more comorbidities (Figure 2B). Figure 3 shows Kaplan Meier 
curves from the primary endpoint according to 0, 1, 2, 3, 4+ comorbidities on 
ivabradine (left) and placebo (right). The numbers of cardiovascular death or heart 
failure hospitalizations were increased with cumulative comorbidity load for both 
placebo and ivabradine. We grouped patients also for 0, 1-2 and 3+ comorbidities 
with similar results. The event rates in each group tended to be lower with ivabradine 
when compared with placebo in patients with 0 or 3+ comorbidities. There was a 
highly significant association (p<0.0001) between comorbidities and cardiovascular 
death and first heart failure hospitalization in both groups (not shown). Hospitalization 
rate was lower in all groups on ivabradine.  Figure 4 shows the association of 0, 1, 2, 
3, 4+ comorbidities on the primary endpoint (A), heart failure hospitalization (B), heart 
failure mortality (C), cardiovascular mortality (D), non-cardiovascular hospitalization 
(E) and total hospitalization (F) on ivabradine (left) and placebo (right). Comorbidities 
were related to outcomes with 3 and for 4+ comorbidities had constantly higher event 
rates. For the majority of endpoints, eGFR was the strongest predictor. For all-cause 
hospitalization and non-CV hospitalization, COPD was most predictive.  
In Suppl. Table 1-4 (Supplementary material), similar  data of the effect of 
comorbidities on the primary endpoint and its components as well as on heart failure 
mortality, all-cause mortality, cardiovascular (CV) hospitalization, total hospitalization 
and non-CV hospitalization are summarized. Mean heart rates at baseline did not 
show clinically meaningful differences significant across the different comorbidity 
groups (Table 1).  
To study whether the comorbidity load had an impact on the treatment effects 
of ivabradine, we investigated the HRs for the primary and secondary endpoint.  
Figure 5 summarizes Forest plots for the treatment effect of ivabradine versus 
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placebo. Again, for all mortality and morbidity outcomes, there was a significant effect 
or a trend in favor of the superiority of ivabradine compared with placebo. No 
significant heterogeneity of the treatment effect of ivabradine was observed between 
the comorbidity groups or different endpoints. In addition, there was no obvious effect 
of an increased load of comorbidities on the size of the treatment effect of ivabradine 
(Table 2). For all outcomes, as well as for all groups of different comorbidities, a 
trend without any evidence of heterogeneity was observed in favor of the treatment 
effect of ivabradine. Similar adjusted and non-adjusted patients were obtained when 
0, 1, 2, 3, 4+ groups were evaluated (Suppl. Table 5 and Suppl. Table 6).  
 
Discussion  
This post-hoc analysis from the SHIFT study demonstrates that cardiac and 
non-cardiac comorbidities are associated with mortality and morbidity.  In SHIFT, the 
most common comorbidities are hypertension, and having a history of myocardial 
infarction, diabetes, impaired renal function and COPD. The majority of patients in 
this population had 1, 2 or 3 accompanying comorbidities. The treatment effect of 
heart rate lowering with ivabradine was maintained for all comorbidity loads.  
The presentation of chronic heart failure syndrome becomes increasingly 
complex due to continuous ageing, leading to a higher rate of ageing-related non-
cardiovascular and cardiovascular comorbidities, hospitalization rates (7) and 
treatment costs (5-6). In addition to the influence of comorbidities on heart failure 
morbidity and mortality, in the absence of overt heart failure, comorbidities such as 
renal dysfunction, reduced forced expiratory volume, low hemoglobin concentration, 
and high white blood cell count increase the incidence of new-onset heart failure 
(12). As pointed out in the ESC Heart Failure Guidelines, comorbidities make the 
treatment of heart failure more complex as many drugs like ACE-inhibitors, ARBs and 
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mineralocorticoid antagonists have limitations, when renal function is impaired (13). 
In this contemporary, treated heart-failure population from SHIFT, similar 
comorbidities like coronary artery disease, COPD, renal impairment and diabetes 
were observed. This pattern differs from that seen in populations studied in earlier 
seminal studies such as SOLVD (Studies Of Left Ventricular Dysfunction)-Prevention 
and SOLVD-Treatment trials (8). Similar or even higher numbers of comorbidities 
were observed in patients in the earlier populations with preserved ejection fraction 
(7). The effect of e3 comorbidities on the primary outcome of SHIFT is most marked, 
outcomes tended to be worse in patients with no comorbidities than in patients with 1 
or 2 comorbidities. There is no obvious explanation for this counter-intuitive finding. 
This observation may be related to the fact that relatively few patients had no 
comorbidities, possibly potentiating chance findings or giving more weight to 
presence of some specific types of comorbidities than to others. This remains an 
open issue.  However, it is nonetheless noteworthy that the effect of ivabradine was 
similar in all 3 morbidity related groups, and that the difference in outcome between 
those with 0 versus 1-2 comorbidities was minimized after treatment with ivabradine. 
Another potential explanation is the fact that we selected only a limited number of 
comorbidities. Therefore, comorbid factors such as falls or cognitive disorders which 
are associated with poor outcome were not considered in our analysis. 
Heart rate reduction with ivabradine reduces the composite endpoint of 
cardiovascular death and heart failure hospitalization at heart rates e70 bpm (10,11) 
and even cardiovascular death and all-cause death in patients  with a heart rate e75 
bpm (14). According to previous analyses from SHIFT, the treatment effect of 
ivabradine was maintained in patients at particularly high risk due to single 
comorbidities or cardiac conditions like impaired renal function (15), chronic 
obstructive pulmonary disease (16) and advanced age (17). In patients with 
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particularly low ejection fraction (<25%) and severe heart failure (NYHA III–IV), the 
treatment effect of ivabradine was similar when compared with milder stages (18). 
However, the important question remains whether treatment effects are impaired by 
an increased comorbidity load in heart failure patients. This report on contemporary 
patients on evidence-based treatment extends those of the SOLVD-Prevention and 
SOLVD-Treatment trial, where patients recruited in the late 1980’s had a similar 
distribution of comorbidities (8). Since in these previous reports (8), the effect of 
comorbidities on outcomes is greater than those of the treatment effects, it becomes 
evident that a greater emphasis has to be on treatments specifically addressing 
comorbidities.  These treatments need to be evaluated in prospective randomized 
trials addressing preventable hospitalizations related to non-cardiovascular 
comorbidities, which amount to almost half of all hospitalizations after the diagnosis 
of chronic heart failure (19).  
Comorbidities might result in a change of the substrate and target of 
treatments. However, we could not observe an effect of comorbidity load on heart 
rate since eligibility and effectiveness for treatment with ivabradine is dependent on 
heart rate (11). It is important to note that no clinically relevant differences in baseline 
heart rates were observed in the different groups. A direct interaction with the 
pathophysiology of heart failure is more likely, in particular with respect to increased 
morbidity. Chronic pulmonary disease aggravates dyspnea (20) and has the potential 
to contribute to impaired LV filling (21). Renal impairment contributes to heart failure, 
which is related to sodium and water retention, exacerbating congestion (22), while 
anemia imposes an increased volume load on the heart leading to an aggravation of 
symptoms (23). All of these chronic conditions impose an increased oxidative stress 
on the cardiovascular system, which can be related to increased mortality rates. 
Interestingly, ivabradine can reduce oxidative stress (24), and heart rate is 
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associated with cognitive (25,26) and renal comorbidities in high risk patients (27), 
potentially providing a target of this treatment.  
This is a post-hoc analysis of a study population not subject to randomization, 
which might lead to bias. In clinical trials, elderly individuals are underrepresented 
(28). Elderly patients have a higher comorbidity load (2,13) with higher levels of non-
adherence to drugs (5), drug interactions  and different sensitivity to the perception of 
heart failure symptoms (29). However, patients aged 69 years and older are 
sufficiently represented in SHIFT, and age has been shown not to influence treatment 
outcomes (17). Finally, self-reporting of comorbidities, as is usually done in trials, can 
lead to over- and underestimation of comorbidities. Chronic obstructive pulmonary 
disease is usually overestimated (by self-reporting), while cancer and renal function 
are underreported with reliable reporting of diabetes and heart disease (30).  
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Figure legends  
Figure 1  
Distribution of different comorbidities according to type in patients on ivabradine or 
placebo. COPD (chronic obstructive pulmonary disease), diabetes mellitus, GFR 
(glomerular filtration rate) < 60 ml, MI (myocardial infarction), PAD (peripheral artery 
disease).  
 
Figure 2  
Distribution of the number of comorbidities in patients on ivabradine or placebo (A) 
and distribution of different comorbidity load (0, 1–2, 3+) on ivabradine or placebo 
(B).  
 
Figure 3  
Kaplan Meier cumulative event curves for the primary endpoint (cardiovascular 
death, hospitalization for heart failure according to 0, 1, 2, 3 and 4+ comorbidities on 
ivabradine (left) or on placebo (right).  
 
Figure 4  
Difference of the number of comorbidities (0, 1, 2, 3 and 4+ comorbidities) and 
hazard ratios (HR) for the primary endpoint cardiovascular death or hospitalization for 
heart failure (A), heart failure hospitalization (B), heart failure mortality (C), 
cardiovascular death (D), non-cardiovascular hospitalization (E) and total 
hospitalization (F) on ivabradine (left) or on placebo (right). P-values were adjusted 
for beta blocker use, New York Heart Association Class, left ventricular ejection 
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fraction, heart rate, ischemic or non-ischemic pathology, age and systolic blood 
pressure.  
 
Figure 5  
Effects of different comorbidity loads on hazard ratios (HR) for the primary endpoint 
(cardiovascular death or hospitalization for heart failure), cardiovascular (CV) and all-
cause mortality, heart failure (HF) hospitalization, HF mortality, all-cause mortality, 
CV hospitalization, total hospitalization and CV hospitalization. P-values were 
adjusted for beta blocker use, New York Heart Association (NYHA) class, left 
ventricular ejection fraction, heart rate, ischemic or non-ischemic pathology, age and 
systolic blood pressure (SBP).  
 
 
Table 1: Baseline characteristics 
Values are presented as means±standard deviations or numbers and percentages (%). 
Baseline characteristics All patients 
(n=6505) 
No comorbidities 
(n=685) 
1-2 comorbidities 
(n=3442) 
3+ comorbidities 
(n=2378) 
P (trend) 
 
Comorbidities, n      
 COPD 730 (11.2%) 0 234 (6.8%) 496 (20.9%) <0.001 
 Diabetes 1979 (30.4%) 0 587 (17.1%) 1392 (58.5%) <0.001 
 Anaemia < 120 492 (7.6%) 0 123 (3.6%) 369 (15.5%) <0.001 
 Stroke 523 (8.0%) 0 103 (3.0%) 420 (17.7%) <0.001 
 EGFR < 60 1697 (26.1%) 0 458 (13.3%) 1239 (52.1%) <0.001 
 MI 3666 (56.4%) 0 1744 (50.7%) 1922 (80.8%)  <0.001 
 Hypertension 4314 (66.3%) 0 2150 (62.5%) 2164 (91.0%) <0.001 
 PVD 407 (6.3%) 0 50 (1.5%) 357 (15.0%) <0.001 
      
EGFR 74.6 (22.9) 90.4 (22.1) 78.7 (20.4) 64.1 (22.1) <0.001 
Age (years) 60.9 (11.4) 51.2 (12.7) 59.9 (10.9) 65.1 (9.4) <0.001 
Male, n 4970 (76.4%) 546 (79.7%) 2696 (78.3%) 1728 (72.7%) <0.001 
Ethnic origin, n      
 White 5771 (88.7%) 505 (73.7%) 3034 (88.1%) 2232 (93.9%) <0.001 
 Asian 532 (8.2%) 148 (21.6%) 278 (8.1%) 106 (4.5%)  
 Other 202 (3.1%) 32 (4.7%) 130 (3.8%) 40 (1.7%)  
Current smokers, n 1118 (17.2%) 122 (17.8%) 648 (18.8%) 348 (14.6%) <0.001 
Body mass index (kg/m2) 
mean (SD) 28.0 (5.1) 25.9 (5.0) 27.9 (5.0) 28.7 (5.0) <0.001 
Resting heart rate (bpm) 
mean (SD) 79.9 (9.6) 81.8 (11.1) 79.6 (9.4) 79.7 (9.5) <0.001 
Systolic blood pressure 
(mmHg), mean (SD) 121.7 (16.0) 112.5 (14.1) 121.5 (15.8) 124.6 (15.6) <0.001 
Diastolic blood pressure 
(mmHg), mean (SD) 75.7 (9.5) 71.8 (8.7) 76.0 (9.6) 76.3 (9.3) <0.001 
LVEF (%), mean (SD) 29.0 (5.2) 27.3 (5.7) 29.0 (5.1) 29.4 (5.0) <0.001 
NYHA Class III/IV, n 3334 (51.3%) 292 (42.7%) 1643 (47.7%) 1399 (58.9%) <0.001 
Ischemic heart failure, n 4418 (67.9%) 83 (12.1%) 2243 (65.2%) 2092 (88.0%) <0.001 
History of atrial fibrillation 
or flutter, n 522 (8.0%) 33 (4.8%) 249 (7.2%) 240 (10.1%) <0.001 
History of dyslipidaemia, n 1221 (18.8%) 55 (8.0%) 625 (18.2%) 541 (22.8%) <0.001 
ACE inhibitor*, n 5116 (78.6) 527 (76.9%) 2731 (79.3%) 1858 (78.1%) 0.981 
ARB*, n 927 (14.3%) 82 (12.0%) 470 (13.7%) 375 (15.8%) 0.004 
Diuretic*, n 5414 (83.2%) 582 (85.0%) 2771 (80.5%) 2061 (86.7%) <0.001 
Aldosterone*, n 3922 (60.3%) 514 (75.0%) 2049 (59.5%) 1359 (57.1%) <0.001 
Beta-blocker*, n 5820 ( 89.5%) 620 ( 90.5%) 3129 (90.9%) 2071 (87.1%) <0.001 
Ivabradine*, n 3241 (49.8%) 325 (47.4%) 1758 (51.1%) 1158 (48.7%) 0.682 
*At randomization 
 
Table 2: Ivabradine vs Placebo 
   0 comorbidities 
1-2 
comorbidities 
3+ 
comorbidties Interaction p values 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value trend test 
Heteroge-
neity test 
Primary 
Endpoint 
68 
(20.9%) 
101 
(28.1%) 
0.74 
(0.54, 1.01) 0.055 
0.81 
(0.70, 0.93) 0.0027 
0.88 
(0.76, 1.02) 0.082 0.18 0.48 
CV-cause 
mortality 
38 
(11.7%) 
55 
(15.3%) 
0.76 
(0.50, 1.16) 0.20 
0.94 
(0.78, 1.14) 0.54 
0.93 
(0.77, 1.14) 0.49 0.52 0.66 
HF 
hospitalisation 
44 
(13.5%) 
75 
(20.8%) 
0.64 
(0.44, 0.94) 0.022 
0.72 
(0.61, 0.86) 0.0002 
0.81 
(0.69, 0.96) 0.017 0.13 0.40 
HF mortality 13 (4.0%) 
19 
(5.3%) 
0.75 
(0.37, 1.52) 0.42 
0.86 
(0.60, 1.24) 0.43 
0.67 
(0.46, 0.98) 0.038 0.54 0.69 
All-cause 
mortality 
42 
(12.9%) 
55 
(15.3%) 
0.85 
(0.56, 1.27) 0.42 
0.95 
(0.79, 1.13) 0.53 
0.90 
(0.75, 1.08) 0.25 0.99 0.87 
CV 
hospitalisation 
81 
(24.9%) 
110 
(30.6%) 
0.76 
(0.57, 1.01) 0.061 
0.82 
(0.72, 0.93) 0.0022 
0.92 
(0.81, 1.04) 0.18 0.11 0.33 
Total 
hospitalisation 
94 
(28.9%) 
122 
(33.9%) 
0.79 
(0.60, 1.04) 0.086 
0.87 
(0.77, 0.97) 0.013 
0.95 
(0.85, 1.06) 0.37 0.13 0.35 
Non-CV 
hospitalisation 
34 
(10.5%) 
40 
(11.1%) 
0.92 
(0.58, 1.46) 0.73 
0.99 
(0.82, 1.19) 0.90 
0.89 
(0.74, 1.07) 0.23 0.58 0.74 
 
Values are presented as numbers and percentages (%) 
(Adjusted for beta-blocker use, NYHA Class, LVEF, heart rate, ischaemia, age and SBP) 
Suppl. Table 1 – SHIFT COMORBIDITIES ANALYSIS (unadjusted) 
A – Ivabradine only 
 0 
(reference) 
1 
HR (95% CI), p-value 
2 
HR (95% CI), p-value 
3 
HR (95% CI), p-value 
4+ 
HR (95% CI), p-value 
Overall 
p-value 
Primary Endpoint 1 0.90 (0.68, 1.20), 0.48 1.02 (0.78, 1.34), 0.89 1.24 (0.94, 1.63), 0.13 1.92 (1.44, 2.54), <0.0001 <0.0001 
HF hospitalisation 1 0.93 (0.65, 1.32), 0.68 0.93 (0.66, 1.31), 0.68 1.29 (0.92, 1.82), 0.15 2.07 (1.46, 2.93), <0.0001 <0.0001 
HF mortality 1 0.72 (0.36, 1.43), 0.35  0.76 (0.40, 1.44), 0.39  0.56 (0.27, 1.14), 0.11 1.71 (0.89, 3.29), 0.11 0.0012 
Non-CV 
hospitalisation 
1 0.99 (0.66, 1.49), 0.98  1.44 (1.00, 2.10), 0.052  1.46 (1.00, 2.15), 0.053 2.47 (1.67, 3.64), <0.0001 <0.0001 
Total 
hospitalisation 
1 0.99 (0.78, 1.26), 0.92  1.29 (1.03, 1.61), 0.029  1.59 (1.26, 2.00), <0.0001 2.39 (1.89, 3.04), <0.0001 <0.0001 
All-cause 
mortality 
1 0.90 (0.62, 1.30), 0.57 1.17 (0.83, 1.64), 0.37 1.09 (0.77, 1.56), 0.63 1.84 (1.29, 2.64), 0.0008 <0.0001 
CV-cause 
mortality 
1 0.89 (0.61, 1.32), 0.57  1.14 (0.80, 1.63), 0.47 1.11 (0.76, 1.62), 0.58  1.78 (1.22, 2.60), 0.0029 0.0001 
CV hospitalisation 1 0.87 (0.67, 1.13), 0.30 1.12 (0.87, 1.43), 0.39 1.36 (1.06, 1.75), 0.016 2.18 (1.69, 2.83), <0.0001 <0.0001 
 
B – Placebo only 
 0 
(reference) 
1 
HR (95% CI), p-value 
2 
HR (95% CI), p-value 
3 
HR (95% CI), p-value 
4+ 
HR (95% CI), p-value 
Overall 
p-value 
Primary Endpoint 1 0.74 (0.57, 0.95), 0.017 0.90 (0.72, 1.14), 0.39 1.02 (0.81, 1.30), 0.84 1.52 (1.20, 1.94), 0.0007 <0.0001 
HF hospitalisation 1 0.68 (0.50, 0.91), 0.0098 0.85 (0.65, 1.12), 0.25 1.02 (0.78, 1.34), 0.90 1.51 (1.14, 2.00), 0.0040 <0.0001 
HF mortality 1 0.64 (0.35, 1.16), 0.14  0.65 (0.37, 1.13), 0.13  0.81 (0.46, 1.42), 0.46 1.53 (0.88, 2.66), 0.13 0.0012 
Non-CV 
hospitalisation 
1 1.14 (0.79, 1.66), 0.48  1.15 (0.80, 1.63), 0.45  1.50 (1.05, 2.14), 0.025 2.40 (1.68, 3.44), <0.0001 <0.0001 
Total 
hospitalisation 
1 0.96 (0.77, 1.19), 0.69  1.11 (0.90, 1.36), 0.33  1.33 (1.08, 1.64), 0.0065 1.97 (1.59, 2.44), <0.0001 <0.0001 
All-cause 
mortality 
1 0.89 (0.64, 1.23), 0.47 0.95 (0.70, 1.29), 0.73 1.05 (0.77, 1.45), 0.74 1.64 (1.19, 2.26), 0.0025 <0.0001 
CV-cause 
mortality 
1 0.79 (0.56, 1.10), 0.16 0.85 (0.62, 1.16), 0.31 0.88 (0.64, 1.22), 0.46 1.46 (1.05, 2.02), 0.023 <0.0001 
CV hospitalisation 1 0.81 (0.64, 1.02), 0.074 1.01 (0.81, 1.25), 0.94 1.18 (0.94, 1.46), 0.15 1.74 (1.39, 2.19), <0.0001 <0.0001 
 
Suppl. Table 2: SHIFT COMORBIDITIES ANALYSIS (adjusted for beta-blocker use, NYHA Class, LVEF, heart rate, ischaemic, age and SBP) 
A – Ivabradine only 
 0 
(reference) 
1 
HR (95% CI), p-value 
2 
HR (95% CI), p-value 
3 
HR (95% CI), p-value 
4+ 
HR (95% CI), p-value 
Overall 
p-value 
Primary Endpoint 1 0.91 (0.68, 1.23), 0.55 0.98 (0.72, 1.32), 0.88 1.16 (0.85, 1.59), 0.35 1.64 (1.18, 2.29), 0.0036 <0.0001 
HF hospitalisation 1 0.96 (0.66, 1.39), 0.83 0.92 (0.63, 1.34), 0.66 1.25 (0.84, 1.84), 0.27 1.82 (1.21, 2.75), 0.0040 <0.0001 
HF mortality 1 0.86 (0.42, 1.77), 0.68 0.93 (0.45, 1.92), 0.84  0.67 (0.29, 1.53), 0.34 1.84 (0.82, 4.12), 0.14 0.012 
Non-CV 
hospitalisation 
1 1.08 (0.72, 1.64), 0.70 1.64 (1.10, 2.47), 0.016  1.67 (1.09, 2.58), 0.020 2.83 (1.80, 4.44), <0.0001 <0.0001 
Total 
hospitalisation 
1 1.05 (0.81, 1.35), 0.72 1.33 (1.04, 1.71), 0.025  1.63 (1.25, 2.12), 0.0003 2.38 (1.80, 3.14), <0.0001 <0.0001 
All-cause 
mortality 
1 0.95 (0.64, 1.39), 0.78 1.20 (0.82, 1.75), 0.35 1.09 (0.73, 1.64), 0.66 1.70 (1.12, 2.60), 0.014 0.0023 
CV-cause 
mortality 
1 0.93 (0.62, 1.39), 0.73  1.15 (0.77, 1.71), 0.49 1.08 (0.71, 1.66), 0.71  1.60 (1.02, 2.50), 0.040 0.017 
CV hospitalisation 1 0.88 (0.67, 1.17), 0.38 1.06 (0.81, 1.40), 0.67 1.28 (0.96, 1.71), 0.10 1.94 (1.43, 2.64), <0.0001 <0.0001 
 
B – Placebo only 
 0 
(reference) 
1 
HR (95% CI), p-value 
2 
HR (95% CI), p-value 
3 
HR (95% CI), p-value 
4+ 
HR (95% CI), p-value 
Overall 
p-value 
Primary Endpoint 1 0.84 (0.65, 1.09), 0.19 1.12 (0.87, 1.45), 0.39 1.22 (0.93, 1.61), 0.16 1.70 (1.27, 2.26), 0.0004 <0.0001 
HF hospitalisation 1 0.83 (0.61, 1.13), 0.24 1.20 (0.89, 1.62), 0.24 1.42 (1.03, 1.95), 0.032 1.99 (1.42, 2.79), <0.0001 <0.0001 
HF mortality 1 0.85 (0.46, 1.60), 0.62  1.03 (0.55, 1.94), 0.92 1.20 (0.62, 2.33), 0.59 2.13 (1.07, 4.24), 0.032 0.011 
Non-CV 
hospitalisation 
1 1.26 (0.86, 1.86), 0.23 1.32 (0.90, 1.95), 0.16 1.72 (1.14, 2.58), 0.009 2.69 (1.76, 4.11), <0.0001 <0.0001 
Total 
hospitalisation 
1 1.06 (0.84, 1.32), 0.64  1.30 (1.03, 1.63), 0.025  1.52 (1.20, 1.94), 0.0006 2.15 (1.67, 2.77), <0.0001 <0.0001 
All-cause 
mortality 
1 0.96 (0.68, 1.36), 0.82 1.04 (0.74, 1.47), 0.81 1.09 (0.75, 1.57), 0.66 1.55 (1.05, 2.27), 0.026 0.0090 
CV-cause 
mortality 
1 0.84 (0.59, 1.20), 0.34 0.92 (0.64, 1.31), 0.63 0.88 (0.60, 1.30), 0.52 1.34 (0.90, 1.99), 0.15 0.012 
CV hospitalisation 1 0.87 (0.68, 1.11), 0.27 1.14 (0.89, 1.45), 0.29 1.28 (0.99, 1.66), 0.058 1.79 (1.37, 2.35), <0.0001 <0.0001 
 
Suppl. Table 3 – Relationship between numbers of comorbidities and risk of clinical outcomes 
(Unadjusted results) 
A – Ivabradine only (n=3241) 
 0 
comorbidities 
1-2 
comorbidities 
3+ 
comorbidities 
Overall 
p-value 
 (reference) HR (95% CI) p-value HR (95% CI) p-value  
Primary Endpoint 1 0.97 (0.75, 1.26) 0.82 1.48 (1.14, 1.91) <0.0001 <0.0001 
CV-cause mortality 1 1.04 (0.74, 1.46) 0.83 1.35 (0.95, 1.91) 0.091 0.019 
HF hospitalisation 1 0.93 (0.67, 1.28) 0.66 1.56 (1.13, 2.16) <0.0001 <0.0001 
HF mortality 1 0.74 (0.40, 1.36) 0.33 0.97 (0.52, 1.79) 0.92 0.35 
All-cause mortality 1 1.06 (0.76, 1.46) 0.75 1.36 (0.98, 1.90) 0.068 0.014 
CV hospitalisation 1 1.01 (0.80, 1.28) 0.93 1.65 (1.30, 2.09) <0.0001 <0.0001 
Total hospitalisation 1 1.16 (0.93, 1.44) 0.19 1.86 (1.50, 2.32) <0.0001 <0.0001 
Non-CV hospitalisation 1 1.25 (0.87, 1.80) 0.22 1.81 (1.26, 2.60) 0.0013 <0.0001 
 
B – Placebo only (n=3264) 
 0 
comorbidities 
1-2 
comorbidities 
3+ 
comorbidities 
Overall 
p-value 
 (reference) HR (95% CI) p-value HR (95% CI) p-value  
Primary Endpoint 1 0.83 (0.67, 1.04) 0.10 1.20 (0.97, 1.50) 0.10 <0.0001 
CV-cause mortality 1 0.82 (0.61, 1.11) 0.20 1.10 (0.82, 1.48) 0.54 0.011 
HF hospitalisation 1 0.78 (0.61, 1.01) 0.055 1.19 (0.93, 1.54) 0.17 <0.0001 
HF mortality 1 0.64 (0.38, 1.08) 0.094 1.08 (0.65, 1.78) 0.78 0.010 
All-cause mortality 1 0.92 (0.69, 1.24) 0.59 1.27 (0.95, 1.70) 0.11 0.0015 
CV hospitalisation 1 0.92 (0.75, 1.14) 0.45 1.38 (1.12, 1.69) 0.0024 <0.0001 
Total hospitalisation 1 1.04 (0.86, 1.27) 0.67 1.56 (1.28, 1.89) <0.0001 <0.0001 
Non-CV hospitalisation 1 1.14 (0.82, 1.60) 0.43 1.83 (1.31, 2.55) 0.0004 <0.0001 
 
Suppl. Table 4 – Relationship between numbers of comorbidities and risk of clinical outcomes 
(Adjusted for beta-blocker use, NYHA Class, LVEF, heart rate, ischaemic, age and SBP) 
A – Ivabradine only (n=3241) 
 0 
comorbidities 
1-2 
comorbidities 
3+ 
comorbidities 
Overall 
p-value 
 (reference) HR (95% CI) p-value HR (95% CI) p-value  
Primary Endpoint 1 0.93 (0.70, 1.23) 0.62 1.30 (0.96, 1.76) 0.092 0.0001 
CV-cause mortality 1 1.02 (0.70, 1.48) 0.93 1.20 (0.80, 1.81) 0.37 0.27 
HF hospitalisation 1 0.92 (0.65, 1.31) 0.65 1.43 (0.98, 2.08) 0.060 <0.0001 
HF mortality 1 0.85 (0.44, 1.66) 0.64 1.02 (0.49, 2.15) 0.95 0.65 
All-cause mortality 1 1.05 (0.73, 1.49) 0.81 1.23 (0.84, 1.81) 0.28 0.22 
CV hospitalisation 1 0.95 (0.74, 1.23) 0.71 1.43 (1.08, 1.89) 0.012 <0.0001 
Total hospitalisation 1 1.16 (0.92, 1.47) 0.21 1.77 (1.38, 2.29) <0.0001 <0.0001 
Non-CV hospitalisation 1 1.31 (0.89, 1.92) 0.17 1.86 (1.23, 2.81) 0.0032 0.0005 
 
B – Placebo only (n=3264) 
 0 
comorbidities 
1-2 
comorbidities 
3+ 
comorbidities 
Overall 
p-value 
 (reference) HR (95% CI) p-value HR (95% CI) p-value  
Primary Endpoint 1 0.96 (0.76, 1.21) 0.72 1.31 (1.01, 1.70) 0.043 0.0002 
CV-cause mortality 1 0.86 (0.62, 1.20) 0.38 1.02 (0.71, 1.46) 0.92 0.21 
HF hospitalisation 1 0.98 (0.75, 1.30) 0.91 1.51 (1.11, 2.04) 0.0083 <0.0001 
HF mortality 1 0.90 (0.51, 1.59) 0.73 1.43 (0.77, 2.67) 0.26 0.049 
All-cause mortality 1 0.99 (0.72, 1.36) 0.93 1.22 (0.86, 1.73) 0.26 0.081 
CV hospitalisation 1 0.98 (0.79, 1.23) 0.88 1.38 (1.08, 1.76) 0.010 <0.0001 
Total hospitalisation 1 1.15 (0.93, 1.42) 0.20 1.65 (1.31, 2.08) <0.0001 <0.0001 
Non-CV hospitalisation 1 1.27 (0.89, 1.82) 0.20 1.99 (1.35, 2.94) 0.0005 <0.0001 
 
 
Suppl. Table 5 – Ivabradine vs Placebo (unadjusted and adjusted for beta-blocker use, NYHA Class, LVEF, heart rate, ischaemic, age and SBP) 
Interaction p-values between treatment and subgroups (0/1/2/3/4+) (adjusted, unadjusted): 
Primary Endpoint (0.27, 0.31) ; HF hospitalisation (0.24, 0.30) ; HF mortality (0.78, 0.73) ; Non-CV hospitalisation (0.86, 0.96) ; 
Total hospitalisation (0.09, 0.11) ; All-cause mortality (0.68, 0.73) ; CV-cause mortality (0.43, 0.47) ; CV hospitalisation (0.11, 0.11) 
A: Total comorbidities – 0 
   Unadjusted Adjusted 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 68 (20.9%) 101 (28.1%) 0.71 (0.52, 0.96) 0.028 0.74 (0.54, 1.01) 0.028 
HF hospitalisation 44 (13.5%) 75 (20.8%) 0.62 (0.43, 0.90) 0.012 0.64 (0.44, 0.94) 0.022 
HF mortality 13 (4.0%) 19 (5.3%) 0.74 (0.36, 1.49) 0.40 0.75 (0.37, 1.52) 0.42 
Non-CV hospitalisation 34 (10.5%) 40 (11.1%) 0.92 (0.58, 1.45) 0.71 0.92 (0.58, 1.46) 0.73 
Total hospitalisation 94 (28.9%) 122 (33.9%) 0.80 (0.61, 1.04) 0.099 0.79 (0.60, 1.04) 0.086 
All-cause mortality 42 (12.9%) 55 (15.3%) 0.82 (0.55, 1.23) 0.34 0.85 (0.56, 1.27) 0.42 
CV-cause mortality 38 (11.7%) 55 (15.3%) 0.74 (0.49, 1.13) 0.16 0.76 (0.50, 1.16) 0.20 
CV hospitalisation 81 (24.9%) 110 (30.6%) 0.77 (0.57, 1.02) 0.068 0.76 (0.57, 1.01) 0.061 
 
B: Total comorbidities – 1 
   Unadjusted Adjusted 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 145 (19.6%) 154 (22.1%) 0.86 (0.69, 1.09) 0.21 0.90 (0.71, 1.12) 0.34 
HF hospitalisation 96 (13.0%) 105 (15.1%) 0.84 (0.64, 1.11) 0.22 0.88 (0.67, 1.16) 0.36 
HF mortality 22 (3.0%) 24 (3.4%) 0.85 (0.48, 1.51) 0.57 0.87 (0.49, 1.56) 0.65 
Non-CV hospitalisation 78 (10.6%) 90 (12.9%) 0.78 (0.58, 1.06) 0.12 0.78 (0.58, 1.06) 0.11 
Total hospitalisation 215 (29.1%) 238 (34.1%) 0.81 (0.68, 0.98) 0.028 0.83 (0.69, 1.00) 0.053 
All-cause mortality 89 (12.1%) 97 (13.9%) 0.84 (0.63, 1.12) 0.24 0.86 (0.64, 1.14) 0.30 
CV-cause mortality 80 (10.8%) 86 (12.3%) 0.86 (0.63, 1.16) 0.32 0.88 (0.65, 1.19) 0.40 
CV hospitalisation 166 (22.5%) 185 (26.5%) 0.82 (0.66, 1.01) 0.059 0.85 (0.69, 1.05) 0.14 
 
  
C: Total comorbidities – 2 
   Unadjusted Adjusted 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 228 (22.4%) 266 (27.0%) 0.80 (0.67, 0.95) 0.011 0.76 (0.63, 0.90) 0.0019 
HF hospitalisation 134 (13.1%) 186 (18.8%) 0.67 (0.54, 0.84) 0.0004 0.63 (0.51, 0.79) <0.0001 
HF mortality 32 (3.1%) 36 (3.6%) 0.86 (0.54, 1.39) 0.55 0.85 (0.52, 1.37) 0.50 
Non-CV hospitalisation 154 (15.1%) 132 (13.4%) 1.15 (0.90, 1.45) 0.25 1.13 (0.89, 1.42) 0.31 
Total hospitalisation 372 (36.5%) 383 (38.8%) 0.92 (0.80, 1.06) 0.26 0.88 (0.76, 1.02) 0.080 
All-cause mortality 161 (15.8%) 153 (15.5%) 1.02 (0.82, 1.28) 0.85 1.00 (0.80, 1.25) 0.97 
CV-cause mortality 142 (13.9%) 137 (13.9%) 1.01 (0.80, 1.27) 0.96 0.99 (0.78, 1.25) 0.93 
CV hospitalisation 287 (28.1%) 321 (32.5%) 0.84 (0.72, 0.98) 0.032 0.80 (0.68, 0.94) 0.0071 
 
D: Total comorbidities – 3 
   Unadjusted Adjusted 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 191 (26.2%) 227 (29.9%) 0.86 (0.70, 1.04) 0.11 0.87 (0.72, 1.06) 0.16 
HF hospitalisation 128 (17.6%) 167 (22.0%) 0.78 (0.62, 0.98) 0.034 0.79 (0.63, 0.99) 0.043 
HF mortality 17 (2.3%) 34 (4.5%) 0.51 (0.28, 0.91) 0.022 0.52 (0.29, 0.94) 0.031 
Non-CV hospitalisation 111 (15.2%) 129 (17.0%) 0.88 (0.69, 1.14) 0.34 0.87 (0.68, 1.13) 0.30 
Total hospitalisation 309 (42.4%) 341 (44.9%) 0.94 (0.81, 1.10) 0.46 0.94 (0.81, 1.10) 0.44 
All-cause mortality 109 (15.0%) 129 (17.0%) 0.86 (0.67, 1.11) 0.25 0.87 (0.67, 1.12) 0.29 
CV-cause mortality 100 (13.7%) 108 (14.2%) 0.94 (0.72, 1.24) 0.67 0.96 (0.73, 1.26) 0.77 
CV hospitalisation 240 (33.0%) 279 (36.8%) 0.88 (0.74, 1.05) 0.16 0.89 (0.75, 1.06) 0.17 
 
E: Total comorbidities – 4 
   Unadjusted Adjusted 
 Ivabradine Placebo HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 161 (37.4%) 189 (41.0%) 0.89 (0.72, 1.10) 0.28 0.88 (0.72, 1.09) 0.25 
HF hospitalisation 112 (26.0%) 139 (30.2%) 0.84 (0.66, 1.08) 0.18 0.83 (0.65, 1.07) 0.15 
HF mortality 29 (6.7%) 38 (8.2%) 0.83 (0.51, 1.35) 0.46 0.82 (0.50, 1.34) 0.43 
Non-CV hospitalisation 100 (23.3%) 117 (25.4%) 0.93 (0.72, 1.22) 0.61 0.91 (0.70, 1.19) 0.49 
Total hospitalisation 241 (56.0%) 272 (59.0%) 0.97 (0.81, 1.15) 0.70 0.95 (0.80, 1.13) 0.58 
All-cause mortality 102 (23.7%) 118 (25.6%) 0.94 (0.72, 1.22) 0.62 0.92 (0.71, 1.20) 0.55 
CV-cause mortality 89 (20.7%) 105 (22.8%) 0.92 (0.69, 1.22) 0.55 0.90 (0.68, 1.20) 0.48 
CV hospitalisation 203 (47.2%) 227 (49.2%) 0.96 (0.79, 1.16) 0.66 0.95 (0.79, 1.15) 0.62 
 
Suppl. Table 6 – Ivabradine vs Placebo  
(unadjusted and adjusted for beta-blocker use, NYHA Class, LVEF, heart rate, ischaemic, age and SBP) 
A: Total comorbidities – 0 
 Ivabradine Placebo Unadjusted Adjusted 
   HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 68 (20.9%) 101 (28.1%) 0.71 (0.52, 0.96) 0.028 0.74 (0.54, 1.01) 0.055 
CV-cause mortality 38 (11.7%) 55 (15.3%) 0.74 (0.49, 1.13) 0.16 0.76 (0.50, 1.16) 0.20 
HF hospitalisation 44 (13.5%) 75 (20.8%) 0.62 (0.43, 0.90) 0.012 0.64 (0.44, 0.94) 0.022 
HF mortality 13 (4.0%) 19 (5.3%) 0.74 (0.36, 1.49) 0.40 0.75 (0.37, 1.52) 0.42 
All-cause mortality 42 (12.9%) 55 (15.3%) 0.82 (0.55, 1.23) 0.34 0.85 (0.56, 1.27) 0.42 
CV hospitalisation 81 (24.9%) 110 (30.6%) 0.77 (0.57, 1.02) 0.068 0.76 (0.57, 1.01) 0.061 
Total hospitalisation 94 (28.9%) 122 (33.9%) 0.80 (0.61, 1.04) 0.099 0.79 (0.60, 1.04) 0.086 
Non-CV hospitalisation 34 (10.5%) 40 (11.1%) 0.92 (0.58, 1.45) 0.71 0.92 (0.58, 1.46) 0.73 
 
B: Total comorbidities – 1-2 
 Ivabradine Placebo Unadjusted Adjusted 
   HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 373 (21.2%) 420 (24.9%) 0.82 (0.71, 0.94) 0.0055 0.81 (0.70, 0.93) 0.0027 
CV-cause mortality 222 (12.6%) 223 (13.2%) 0.94 (0.78, 1.14) 0.54 0.94 (0.78, 1.14) 0.54 
HF hospitalisation 230 (13.1%) 291 (17.3%) 0.73 (0.62, 0.87) 0.0004 0.72 (0.61, 0.86) 0.0002 
HF mortality 54 (3.1%) 60 (3.6%) 0.86 (0.59, 1.24) 0.40 0.86 (0.60, 1.24) 0.43 
All-cause mortality 250 (14.2%) 250 (14.8%) 0.95 (0.80, 1.13) 0.55 0.95 (0.79, 1.13) 0.53 
CV hospitalisation 453 (25.8%) 506 (30.0%) 0.83 (0.73, 0.94) 0.0041 0.82 (0.72, 0.93) 0.0022 
Total hospitalisation 587 (33.4%) 621 (36.9%) 0.88 (0.78, 0.98) 0.023 0.87 (0.77, 0.97) 0.013 
Non-CV hospitalisation 232 (13.2%) 222 (13.2%) 0.99 (0.83, 1.19) 0.94 0.99 (0.82, 1.19) 0.90 
 
C: Total comorbidities – 3+ 
 Ivabradine Placebo Unadjusted Adjusted 
   HR (95% CI) p-value HR (95% CI) p-value 
Primary Endpoint 352 (30.4%) 416 (34.1%) 0.87 (0.75, 1.00) 0.053 0.88 (0.76, 1.02) 0.082 
CV-cause mortality 189 (16.3%) 213 (17.5%) 0.92 (0.76, 1.12) 0.43 0.93 (0.77, 1.14) 0.49 
HF hospitalisation 240 (20.7%) 306 (25.1%) 0.81 (0.68, 0.95) 0.012 0.81 (0.69, 0.96) 0.017 
HF mortality 46 (4.0%) 72 (5.9%) 0.67 (0.46, 0.96) 0.031 0.67 (0.46, 0.98) 0.038 
All-cause mortality 211 (18.2%) 247 (20.2%) 0.89 (0.74, 1.07) 0.21 0.90 (0.75, 1.08) 0.25 
CV hospitalisation 443 (38.3%) 506 (41.5%) 0.91 (0.80, 1.04) 0.16 0.92 (0.81, 1.04) 0.18 
Total hospitalisation 550 (47.5%) 613 (50.2%) 0.95 (0.85, 1.07) 0.38 0.95 (0.85, 1.06) 0.37 
Non-CV hospitalisation 211 (18.2%) 246 (20.2%) 0.90 (0.75, 1.08) 0.26 0.89 (0.74, 1.07) 0.23 
 
 
66.7	  
56.4	  
30.0	  
25.9	  
11.1	  
7.6	   7.0	   6.5	  
65.9	  
56.3	  
30.8	  
26.3	  
11.4	  
7.6	   9.0	   6.0	  
0	  
10	  
20	  
30	  
40	  
50	  
60	  
70	  
80	  
Hypertension	   MI	   Diabetes	   GFR<60ml	   COPD	   Anaemia	   Stroke	   PAD	  
(%)	  
Ivabradine	  
Placebo	  
Figure	  1	  –	  DistribuQon	  of	  ComorbidiQes	  
10.0% 
22.8% 
31.5% 
22.5% 
8.9% 
3.7% 
0.6% 0.1% 
11.0% 
21.4% 
30.2% 
23.3% 
9.7% 
3.7% 
0.6% 0.1% 
0.00%	  
5.00%	  
10.00%	  
15.00%	  
20.00%	  
25.00%	  
30.00%	  
35.00%	  
0	   1	   2	   3	   4	   5	   6	   7	  
Number	  of	  Comorbidi7es	  
Ivabradine	  
Placebo	  
Figure	  2	  –	  Distribu7on	  of	  Comorbidity	  Numbers	  
10.0% 
54.2% 
35.7% 
11.0% 
51.6% 
37.4% 
0%	  
10%	  
20%	  
30%	  
40%	  
50%	  
60%	  
0	   1-­‐2	   3+	  
Number	  of	  Comorbidi7es	  
A	   B	  
0 comorbidities 1 comorbidity 2 comorbidities 
Figure 3: Primary Endpoint by Number of Comorbidities  
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